Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | YAP1 | P46937 | 1/20 | 0.53 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949555 | 0.81 | TSHR (0.61) | TSHRALDH1A1YAP1TEAD4RECQL | |
| SCHEMBL5949547 | 0.81 | TSHR (0.61) | TSHRALDH1A1YAP1TEAD4RECQL | |
| SCHEMBL4892974 | 0.79 | USP2 (0.62) | TSHRALDH1A1YAP1TEAD4RECQL | |
| SCHEMBL4815957 | 0.78 | USP2 (0.78) | TSHRALDH1A1YAP1TEAD4RECQL | |
| SCHEMBL7356750 | 0.78 | USP2 (0.78) | TSHRALDH1A1YAP1TEAD4RECQL | |
| SCHEMBL18864777 | 0.78 | TSHR (0.71) | TSHRALDH1A1YAP1TEAD4KMT2A | |
| SCHEMBL7222883 | 0.78 | TSHR (0.71) | TSHRALDH1A1YAP1TEAD4KMT2A | |
| SCHEMBL21593709 | 0.77 | TSHR (0.69) | TSHRALDH1A1YAP1TEAD4KMT2A | |
| SCHEMBL30047393 | 0.77 | TSHR (0.69) | TSHRALDH1A1YAP1TEAD4KMT2A | |
| SCHEMBL8223285 | 0.75 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | ETERNYGEN GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | ETERNYGEN GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | CS, SLC2A1, SLC2A2 | TSHR 900/4885ALDH1A1 737/4885YAP1 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.